Ligand Reports First Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Travere Therapeutics (TVTX) Tops Q1 EPS by 115c
May 4, 2023 5:02 PM EDTTravere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.09), $1.15 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $44 million versus the consensus estimate of $50.6 million.
For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.
... MoreLigand Pharma (LGND) Tops Q1 EPS by $1.42; Offers FY23 Guidance
May 4, 2023 4:56 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $2.28, $1.42 better than the analyst estimate of $0.86. Revenue for the quarter came in at $44 million versus the consensus estimate of $32 million.
GUIDANCE:
Ligand Pharma sees FY2023 EPS of $4.60-$4.75, versus the consensus of... More
